PROTECTIVE IMMUNITY TO HBV IN HIV+ PATIENTS WITH ISOLATED HBV CORE ANTIBODY

具有分离的 HBV 核心抗体的 HIV 患者对 HBV 的保护性免疫

• 批准号: 7718203
• 负责人: DAWN A FISHBEIN
• 金额: $ 7.06万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-03-01 至 2009-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7718203
• 关键词: Antibodies; Cause of Death; Communicable Diseases; Computer Retrieval of Information on Scientific Projects Database; Epidemic; Funding; Grant; HIV; Hepatitis B Core Antigen; Hepatitis B Virus; Hepatitis C virus; High Prevalence; Immunity; Immunologics; Individual; Infection; Institution; Outcome; Patients; Pattern; Recommendation; Reporting; Research; Research Personnel; Resources; Risk; Serological; Simian B disease; Source; Surface Antigens; United States National Institutes of Health; Vaccination; Viremia; response; viral DNA; virus core

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hepatitis B Virus (HBV) remains one of the most common infectious diseases worldwide, ranking behind HIV as the 10th leading cause of death. The serologic pattern, definitions and outcomes of HBV infection are extremely complicated, resulting in widely variable HBV vaccination and treatment recommendations. One marker of prior HBV infection is the antibody to hepatitis B core antigen (anti-HBc). However, certain patients have an "isolated anti-HBc" without any other serologic evidence of HBV, and thus no clear evidence of protective immunity with antibodies to HBV surface antigen (anti-HBs). A high prevalence of isolated anti-HBc has been reported in those with HIV (13-40%), HCV (20 -30%) and HIV/HCV (up to 80%). Studies have shown a proportion of individuals with isolated anti-HBc are carriers of HBV, with detectable viremia or HBV DNA in approximately 10-30%. Our objective is to determine the response to vaccination in those with isolated anti-HBc and without detectable HBV DNA. We will use the antibody titer in response to a single vaccination as indicative of prior infection (high titer, or anamnestic response) or no prior infection (low titer, or primary response). Given the epidemic it is essential that we ascertain the immunologic significance of an isolated anti-HBc, especially in high-risk groups, such as HIV and HCV patients.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 丙型肝炎病毒（HBV）仍然是全球最常见的传染病之一，落后于艾滋病毒，是第十个主要的死亡原因。 HBV感染的血清学模式，定义和结果极为复杂，导致HBV疫苗接种和治疗建议差异很大。 先前HBV感染的一个标记是丙型肝炎核抗原（抗HBC）的抗体。 然而，某些患者没有任何其他HBV的血清学证据，因此具有“孤立的抗HBC”，因此没有明确的证据证明具有HBV表面抗原（抗HBS）抗体的保护性免疫。 据报道，在HIV（13-40％），HCV（20 -30％）和HIV/HCV（高达80％）的患者中，已经报道了孤立的抗HBC的高患病率。 研究表明，具有孤立抗HBC的个体比例是HBV的载体，可检测到的病毒血症或HBV DNA约为10-30％。 我们的目标是确定孤立抗HBC且没有可检测的HBV DNA的人对疫苗接种的反应。 我们将使用抗体滴度来响应单个疫苗接种，以表示先前感染（高滴度或吞噬反应）或没有事先感染（低滴度或主要反应）。 鉴于流行病至关重要，我们必须确定分离的抗HBC的免疫学意义，尤其是在高危组（例如HIV和HCV患者）中。